Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Written by Customer Service on . Posted in Public Companies.

BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in multiple panels and presentations across three ophthalmology meetings in Chicago, Illinois during October 2024.

Presentation & Panel Details (all times CT):

Eyecelerator® @ AAO 2024: October 17

  • Panel Title: Fueling Progress: The Power of Innovation and Perseverance
    Session: S3
    Panel Date/Time: Thursday, October 17, 10:00 – 11:00 AM
    Ocular Therapeutix Panelist: Pravin U. Dugel, MD, Executive Chair, President and CEO
  • Company Presentation: Ocular Therapeutix: Transformation Into A Retina-focused Company
    Session: Eyecelerator @ AAO 2024 Retina Showcase, Room E450a
    Presentation Date/Time: Thursday, October 17, 1:24 – 1:31 PM
    Presenter: Peter K. Kaiser, MD, Chief Development Officer

Innovate RETINA 2024: October 17

  • Panel Title: The Future of Retinal Therapeutics
    Session: Session 5
    Panel Date/Time: Thursday, October 17, 6:30 PM
    Ocular Therapeutix Panelist: Pravin U. Dugel, MD, Executive Chair, President and CEO

American Academy of Ophthalmology® (AAO 2024): October 18 — 21, Chicago, Illinois

  • Poster Presentation: Fifty-Two-Week Sustained Efficacy and Treatment Burden Reduction with OTX-TKI in the U.S. Phase 1 Trial for nAMD
    Session: PO582, On Demand throughout the meeting
    Presenter: David A. Eichenbaum, MD, FASRS

A full copy of the poster will be available on the “Investors” page of the Ocular website under the “Scientific & Medical Presentations” tab.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.